Gentium is expecting the European Medicines Agency (EMA) to turn down its investigational medicine defibrotide for a liver condition associated with stem cell transplantation. The Italy-based pharma ...

VILLA GUARDIA, Italy, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (GENT) (the "Company") announced today that, the Company had presented an oral explanation at the European Medicines Agency's ...

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including ...

19, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A. (Nasdaq: GENT) today announced that they have entered into a definitive agreement pursuant to which a subsidiary ...

BOSTON (MarketWatch) -- Shares of Gentium SpA tumbled 29% to $6.24 on Thursday, the day after the Italian biotech group withdrew the U.S. marketing application for its drug Defibrotide due to ...

We are pleased to annouce that the American Society of International Law (ASIL) and the International Legal Research IG have awarded the 2021 Jus Gentium Research Award to the United Nations ...

Jazz Pharmaceuticals has entered into support agreements with certain shareholders of Gentium, including members of the board of directors and management team of Gentium, pursuant to which each of ...

Gentium receives marketing authorization for Defitelio (R) for the treatment of severe hepatic veno-occlusive disease. Gentium S.p.A. has reported that the European Commission has granted a marketing ...

BOSTON (MarketWatch) -- Gentium S.p.A, Ardea Biosciences and MDRNA were leading gainers in the drug sector Thursday afternoon. The NYSE Arca Pharmaceutical Index $DRG ...

Lumen Gentium (Light of the Nations), the Second Vatican Council’s dogmatic constitution on the Church, celebrates its golden anniversary on Nov. 21 and is no less relevant today than when it ...